The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the ...

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a ...

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX ...

The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of ...

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of ...